(CercleFinance.com) – Eli Lilly announces that a phase III trial comparing Jardiance and a placebo as treatment for type 2 diabetes in 10-17 year olds has met its primary endpoint by demonstrating ‘a statistically significant reduction in HbA1c’, the marker of average blood sugar.
The laboratory announced these results at the World Congress of the International Diabetes Federation (IDF) which was held today.
He says the overall safety data was generally consistent with previous results seen in adults.
“These results are particularly important given the need for more treatment options to combat type 2 diabetes in young people because, to date, metformin is the only oral treatment available for them,” explained Lori Laffel, in substance. MD, the study’s principal investigator and professor of pediatrics at Harvard Medical School.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
